Traders Buy Eli Lilly and Company (LLY) on Weakness

Investors bought shares of Eli Lilly and Company (NYSE:LLY) on weakness during trading on Monday. $95.07 million flowed into the stock on the tick-up and $54.90 million flowed out of the stock on the tick-down, for a money net flow of $40.17 million into the stock. Of all stocks tracked, Eli Lilly and had the 11th highest net in-flow for the day. Eli Lilly and traded down ($0.29) for the day and closed at $82.63

Several brokerages recently commented on LLY. Berenberg Bank reaffirmed a “buy” rating and set a $98.00 price objective on shares of Eli Lilly and in a research note on Friday, August 4th. Sanford C. Bernstein reaffirmed an “outperform” rating and set a $88.00 price objective on shares of Eli Lilly and in a research note on Sunday, May 21st. TheStreet cut shares of Eli Lilly and from a “b+” rating to a “c” rating in a research note on Wednesday, May 31st. BMO Capital Markets reaffirmed an “underperform” rating and set a $73.00 price objective on shares of Eli Lilly and in a research note on Wednesday, July 26th. Finally, Oppenheimer Holdings, Inc. cut shares of Eli Lilly and from an “outperform” rating to a “market perform” rating and set a $90.00 price objective for the company. in a research note on Wednesday, July 26th. Three investment analysts have rated the stock with a sell rating, seven have issued a hold rating and twelve have given a buy rating to the stock. Eli Lilly and has an average rating of “Hold” and an average price target of $88.07.

The firm has a market capitalization of $86.69 billion, a PE ratio of 35.56 and a beta of 0.34. The firm has a 50 day moving average price of $80.93 and a 200 day moving average price of $82.06.

Eli Lilly and (NYSE:LLY) last posted its earnings results on Tuesday, July 25th. The company reported $1.11 earnings per share for the quarter, beating analysts’ consensus estimates of $1.05 by $0.06. Eli Lilly and had a net margin of 11.12% and a return on equity of 28.71%. The firm had revenue of $5.82 billion during the quarter, compared to analyst estimates of $5.60 billion. During the same period last year, the firm posted $0.86 earnings per share. Eli Lilly and’s revenue for the quarter was up 7.8% compared to the same quarter last year. Equities research analysts predict that Eli Lilly and Company will post $4.16 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which was paid on Friday, September 8th. Investors of record on Tuesday, August 15th were issued a $0.52 dividend. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.53%. The ex-dividend date of this dividend was Friday, August 11th. Eli Lilly and’s dividend payout ratio (DPR) is presently 90.04%.

In related news, major shareholder Lilly Endowment Inc sold 210,000 shares of the firm’s stock in a transaction on Thursday, June 22nd. The shares were sold at an average price of $84.43, for a total value of $17,730,300.00. Following the completion of the transaction, the insider now directly owns 124,265,804 shares of the company’s stock, valued at $10,491,761,831.72. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Over the last three months, insiders sold 825,000 shares of company stock valued at $68,456,650. 0.20% of the stock is currently owned by insiders.

Hedge funds have recently bought and sold shares of the stock. Ronna Sue Cohen boosted its stake in Eli Lilly and by 0.4% during the second quarter. Ronna Sue Cohen now owns 2,466 shares of the company’s stock worth $203,000 after buying an additional 9 shares during the period. Accredited Investors Inc. boosted its stake in Eli Lilly and by 0.4% during the second quarter. Accredited Investors Inc. now owns 3,259 shares of the company’s stock worth $268,000 after buying an additional 14 shares during the period. Sunbelt Securities Inc. boosted its stake in Eli Lilly and by 0.5% during the first quarter. Sunbelt Securities Inc. now owns 3,721 shares of the company’s stock worth $313,000 after buying an additional 17 shares during the period. Northwest Quadrant Wealth Management LLC boosted its stake in Eli Lilly and by 0.5% during the first quarter. Northwest Quadrant Wealth Management LLC now owns 3,589 shares of the company’s stock worth $290,000 after buying an additional 19 shares during the period. Finally, Pillar Pacific Capital Management LLC boosted its stake in Eli Lilly and by 0.3% during the first quarter. Pillar Pacific Capital Management LLC now owns 7,077 shares of the company’s stock worth $595,000 after buying an additional 20 shares during the period. 75.77% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: This story was posted by Markets Daily and is the sole property of of Markets Daily. If you are viewing this story on another site, it was illegally copied and reposted in violation of international copyright laws. The original version of this story can be viewed at https://www.themarketsdaily.com/2017/09/13/traders-buy-eli-lilly-and-company-lly-on-weakness.html.

About Eli Lilly and

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply